ZFIN ID: ZDB-PUB-100119-13
Genetic modeling of Li-Fraumeni syndrome in zebrafish
Parant, J.M., George, S.A., Holden, J.A., and Yost, H.J.
Date: 2010
Source: Disease models & mechanisms   3(1-2): 45-56 (Journal)
Registered Authors: Parant, John, Yost, H. Joseph
Keywords: none
MeSH Terms:
  • Alleles
  • Animals
  • Apoptosis/radiation effects
  • DNA Damage
  • Disease Models, Animal
  • Gene Knockdown Techniques
  • Genes, Dominant/genetics
  • Genetic Testing
  • Heterozygote
  • Li-Fraumeni Syndrome/genetics*
  • Loss of Heterozygosity/genetics
  • Models, Genetic*
  • Mutation/genetics
  • Neoplasms/genetics
  • Neoplasms/pathology
  • Protein Stability/radiation effects
  • Proto-Oncogene Proteins c-mdm2/metabolism
  • Radiation, Ionizing
  • Signal Transduction/radiation effects
  • Transcriptional Activation/genetics
  • Transcriptional Activation/radiation effects
  • Tumor Suppressor Protein p53/genetics
  • Tumor Suppressor Protein p53/metabolism
  • Zebrafish/genetics*
PubMed: 20075382 Full text @ Dis. Model. Mech.
Li-Fraumeni syndrome (LFS) is a highly penetrant, autosomal dominant, human familial cancer predisposition. Although a key role for the tumor suppressor p53 has been implicated in LFS, the genetic and cellular mechanisms underpinning this disease remain unknown. Therefore, modeling LFS in a vertebrate system that is accessible to both large-scale genetic screens and in vivo cell biological studies will facilitate the in vivo dissection of disease mechanisms, help identify candidate genes, and spur the discovery of therapeutic compounds. Here, we describe a forward genetic screen in zebrafish embryos that was used to identify LFS candidate genes, which yielded a p53 mutant (p53(I166T)) that as an adult develops tumors, predominantly sarcomas, with 100% penetrance. As in humans with LFS, tumors arise in heterozygotes and display loss of heterozygosity (LOH). This report of LOH indicates that Knudson's two-hit hypothesis, a hallmark of human autosomal dominant cancer syndromes, can be modeled in zebrafish. Furthermore, as with some LFS mutations, the zebrafish p53(I166T) allele is a loss-of-function allele with dominant-negative activity in vivo. Additionally, we demonstrate that the p53 regulatory pathway, including Mdm2 regulation, is evolutionarily conserved in zebrafish, providing a bona fide biological context in which to systematically uncover novel modifier genes and therapeutic agents for human LFS.